Pyrimidinones as Casein Kinase II (CK2) Modulators
申请人:Koltun Elena S.
公开号:US20100144770A1
公开(公告)日:2010-06-10
A compound having Formula I: or a pharmaceutically acceptable salt thereof, wherein X, R, R and R are as defined in the specification; pharmaceutical compositions thereof; and methods of use thereof. The compounds of Formula I are inhibitors of Casein kinase II (CK2) pathways.
具有I式的化合物或其药学上可接受的盐,其中X,R,R和R在说明书中定义;其制药组合物;以及其使用方法。I式化合物是Casein kinase II (CK2)通路的抑制剂。
NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINE THEREOF
申请人:Eisai Co., Ltd.
公开号:EP1484327A1
公开(公告)日:2004-12-08
Compounds represented by the following general formula:
[wherein X1, X2, X3 and X4 each independently represent a single bond, C1-6 alkylene, etc.; A2 represents optionally substituted phenyl, etc.; A1 represents an optionally substituted 5- to 7-membered heterocyclic group containing -C(=Q1)- (wherein Q1 represents oxygen, sulfur or =N-R11 (wherein R11 represents hydrogen or C1-6 alkyl)) and nitrogen, etc.; and Z1 represents piperidin-diyl, etc.],
salts thereof and hydrates of the foregoing.